Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline in a Rare-Disease Pact with Prosensa for RNA-modulation Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.

You may also be interested in...



Tapping Into Top Partnering Opportunities Beyond The Blockbuster

The upcoming Therapeutic Area Partnership conference will showcase companies in niche areas that are prime targets for partnerships or acquisitions.

Partnering Door Opens For Sarepta With 48-Week Data In Hand

Sarepta Therapeutics’ positive data on its lead muscular dystrophy drug eteplirsen puts the company in a strong position at the partnering table and sets the stage for a neck and neck race with GSK/Prosensa to bring the first treatment for the rare disease to market.

Sarepta Therapeutics Off To A Strong Start With New Name And Data

The RNA drug-discovery company, formerly AVI BioPharma, is reinventing itself as an orphan disease drug specialist called Sarepta Therapeutics. With the release of positive Phase IIb data on its lead candidate for Duchenne muscular dystrophy, the transformation has gotten a big boost.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel